A bioprinted animal patient-derived breast cancer model for anti-cancer drug screening
Source abstract
Abstract
Animal models are commonly used for drug screening before clinical trials. However, developing these models is time-consuming, and the results obtained from these models may differ from clinical outcomes due to the differences between animals and humans. To this end, 3D bioprinting offers several advantages for drug screening, such as high reproducibility and improved throughput, in addition to the human cells that can be used to generate these models. Here, we report the development of an animal patient-derived in vitro breast cancer model for drug screening using digital light processing (DLP) bioprinting. These bioprinted models demonstrated good cytocompatibility and preserved phenotypes of the cells. DLP enabled rapid fabrication with blood vessel-like channels to replicate, to a good extent, the tumor microenvironment. Our findings suggested that the improved microenvironment, provided by vascular structures within the bioprinted models, played a crucial role in reducing the chemoresistance of drugs. In addition, the correlation of the in vitro and in vivo drug-screening results was preliminarily performed to evaluate the predictive feasibility of this bioprinted model, suggesting a strategy for the design of future drug-testing platforms.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Innovative Microfluidic and Catalytic Techniques Innovation · Cell Image Analysis Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Systems biology in drug discovery10.1038/nbt1017 ↗
2. The challenges of modeling mammalian biocomplexity10.1038/nbt1015 ↗
3. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery10.1016/j.bcp.2013.06.020 ↗
4. Animal models in translational medicine: validation and prediction
5. Animal models of human disease: challenges in enabling translation10.1016/j.bcp.2013.08.006 ↗
6. Are animal models predictive for humans?10.1186/1747-5341-4-2 ↗
7. Lost in translation: animal models and clinical trials in cancer treatment
8. FDA no longer needs to require animal tests before human drug trials10.1126/science.adg6276 ↗
9. Could 3D models of cancer enhance drug screening?10.1016/j.biomaterials.2019.119744 ↗
10. Revisiting lab-on-a-chip technology for drug discovery10.1038/nrd3799 ↗
11. 3D cell culture systems: advantages and applications10.1002/jcp.24683 ↗
12. 3D bioprinted cancer models: from basic biology to drug development10.1038/s41568-022-00514-w ↗
13. Advances in 3D cell culture technologies enabling tissue-like structures to be created in vitro10.1111/joa.12257 ↗
14. Bridging the gap: from 2D cell culture to 3D microengineered extracellular matrices10.1002/adhm.201500427 ↗
15. Biofabrication strategies for 3D in vitro models and regenerative medicine10.1038/s41578-018-0006-y ↗
16. 3D bioprinting: from benches to translational applications
17. 3D bioprinting for tissue and organ fabrication10.1007/s10439-016-1612-8 ↗
18. From shape to function: the next step in bioprinting10.1002/adma.201906423 ↗
19. Next-generation cancer organoids10.1038/s41563-021-01057-5 ↗
20. Application areas of 3D bioprinting10.1016/j.drudis.2016.04.006 ↗
21. 3D extrusion bioprinting10.1038/s43586-021-00073-8 ↗
22. Photopolymerizable biomaterials and light-based 3D printing strategies for biomedical applications
23. 3D bioprinting of tissues and organs10.1038/nbt.2958 ↗
24. Light-based vat-polymerization bioprinting10.1038/s43586-023-00231-0 ↗
25. Fundamentals and applications of photo-cross-linking in bioprinting10.1021/acs.chemrev.9b00812 ↗
26. Grayscale digital light processing 3D printing for highly functionally graded materials
27. Engineering materials with light: recent progress in digital light processing based 3D printing10.1039/D0TC03548C ↗
28. Digital light processing bioprinting advances for microtissue models10.1021/acsbiomaterials.1c01509 ↗
29. Digital light processing based three-dimensional printing for medical applications10.18063/ijb.v6i1.242 ↗
30. Progress in 3D bioprinting technology for tissue/organ regenerative engineering10.1016/j.biomaterials.2019.119536 ↗
31. Transport of drugs from blood vessels to tumour tissue10.1038/nrc.2017.93 ↗
32. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis Model1
33. The story of MCF-7 breast cancer cell line: 40 years of experience in Research
34. Epigenetics of breast cancer: biology and clinical implication in the era of precision medicine10.1016/j.semcancer.2018.01.007 ↗
35. Ki67 in breast cancer: prognostic and predictive potential10.1016/S1470-2045(09)70262-1 ↗
36. Guidelines for accurate EC50/IC50 estimation10.1002/pst.426 ↗
37. Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening10.1038/s41598-020-79325-8 ↗
38. Effects of cyclophosphamide and/or doxorubicin in a murine model of postchemotherapy cognitive impairment10.1093/toxsci/kfx267 ↗
39. Acute toxicity study of intravenously administered capecitabine resealed erythrocytes in mice10.52711/0974-360X.2022.00923 ↗
40. Dose translation from animal to human studies revisited10.1096/fj.07-9574LSF ↗
41. Feldman · 2014 · 31
42. Opportunities and challenges in phenotypic drug discovery: an industry perspective10.1038/nrd.2017.111 ↗
43. A review of high throughput technology for the screening of natural products10.1016/j.biopha.2007.06.012 ↗
44. Digital light processing (DLP) in tissue engineering: from promise to reality, and perspectives10.1088/1748-605X/ac96ba ↗
45. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin10.1200/JCO.2006.08.4046 ↗
46. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer10.1093/annonc/mdh097 ↗
47. Todd
48. Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening10.18632/oncotarget.4013 ↗
49. Pathophysiologically relevant in vitro tumor models for drug screening10.1016/j.drudis.2015.04.004 ↗
50. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs10.1002/biot.201600505 ↗